Budget 2026 impact on stock market: Which are the top stocks in focus? Check list

India's Budget 2026 surprised markets by doubling STT on F&O futures from 0.02% to 0.05% and raising options premium tax to 0.15% (from 0.1%), prompting an immediate risk-off reaction that dragged Sensex and Nifty into the red after early intraday highs (~82,726 and ~25,357). Higher government borrowing was flagged as a liquidity and yield headwind for banks, while targeted measures — Rs 40,000 crore for local chip fabrication/PCB assembly, a Rs 10,000 crore 'Biopharma Shakti' program, and a long tax holiday for foreign cloud providers using Indian data centers — create clear winners (Amber, Dixon, Biocon, Sun Pharma, ACE/Escorts, Anant Raj, NMDC/GMDC) even as exchanges and retail brokerages (BSE, Groww, Nuvama, Angel One) and bank sentiment face near-term pressure; several names were noted with buy calls by the analyst.

Analysis

Market structure: The derivatives tax hike (F&O STT doubled; options premium tax +50%) is an explicit profit-tax on listed exchanges and retail brokers, likely reducing NSE/BSE and broker F&O volumes by 15–30% over 1–3 months if market participants reprice strategies. Winners are domestic manufacturing and strategic supply-chain plays (Dixon, Amber, NMDC, Biocon, Sun Pharma) benefiting from capex/production incentives; losers are exchanges and retail broking (BSE, Angel One, Groww, Nuvama) and liquidity providers who earn from flow.

Risk assessment: Near-term tail risks include further quick policy tweaks (additional trading curbs or broader financial transaction taxes) or a >25–50bp spike in 10Y yields from higher borrowing that compresses bank bond books; both could amplify mark-to-market losses in broker and exchange names within days–weeks. Hidden second-order effects: lower F&O liquidity raises implied vol and bid-ask spreads, increasing hedging costs for institutional desks and potentially re-routing algorithmic flow off-shore.

Trade implications: Tactical short positions (3–6 months) on exchange/broker equities or buy 3–6 month OTM puts sized 1–2% NAV likely offer asymmetric risk/reward; medium-term (6–24 months) longs in Amber (AMBER), Dixon (DIXON), Biocon (BIOCON), Sun Pharma (SUNPHARMA) and NMDC (NMDC) capture incentive-driven revenue growth. Rotate equity exposure from flow-dependent financials into domestic capex/manufacturing and select pharma/biotech names while keeping duration short in fixed income if yields move +20–30bp.

Contrarian angles: Consensus assumes permanent lower F&O volumes; this may be overdone if brokers absorb tax or push product-fees, restoring volumes within 6–9 months — that would produce sharp rebounds in exchange/broker stocks. Historical parallels: prior STT increases saw 20–40% short-term volume contraction but full recovery in 6–12 months once market microstructure adapted; watch 30-day rolling F&O ADV and broker fee-adjustments as leading indicators.

Key Decisions for Investors

• Establish a 2–3% long position in DIXON and AMBER (1–1.5% each) over a 12–24 month horizon to capture Rs40k crore semiconductor/PCB and local manufacturing incentives; scale in on any 5–12% pullback, target 30–60% upside, stop-loss 20%.
• Initiate 1–2% tactical shorts or buy 3–6 month OTM puts (10–15% OTM) on exchange/broker names: BSE (BSE), ANGELONE (ANGELONE), GROWW (GROWW) and NUVAMA (NUVAMA); increase if 30-day F&O ADV falls >20% versus pre-Budget baseline.
• Overweight NMDC (NMDC) by 1–2% for 6–18 months to play Rare Earth corridor + capex; take profits if iron/rare-metal realization improves and stock rises >40% or if mining regulatory delays exceed 6 months.
• Reduce long-duration sovereign exposure: shift into short-duration (<3yr) bond funds or cash if 10Y INR yield rises >25bp in 30 days; redeploy proceeds into selected manufacturing/pharma names if fiscal-driven capex announcements translate into confirmed order wins within 3 months.